Compare OGS & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGS | IRTC |
|---|---|---|
| Founded | 1906 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.8B |
| IPO Year | 2013 | 2016 |
| Metric | OGS | IRTC |
|---|---|---|
| Price | $87.05 | $123.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $85.25 | ★ $209.69 |
| AVG Volume (30 Days) | 387.0K | ★ 652.0K |
| Earning Date | 05-18-2026 | 05-25-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | 11.76 | ★ 61.71 |
| EPS | ★ 4.37 | N/A |
| Revenue | ★ $2,578,005,000.00 | $747,138,000.00 |
| Revenue This Year | $17.33 | $19.58 |
| Revenue Next Year | N/A | $15.95 |
| P/E Ratio | $19.88 | ★ N/A |
| Revenue Growth | ★ 42.54 | 26.24 |
| 52 Week Low | $69.75 | $92.52 |
| 52 Week High | $87.88 | $210.01 |
| Indicator | OGS | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 65.26 | 31.13 |
| Support Level | $71.95 | N/A |
| Resistance Level | N/A | $167.19 |
| Average True Range (ATR) | 1.78 | 7.72 |
| MACD | -0.11 | -1.21 |
| Stochastic Oscillator | 78.93 | 9.36 |
ONE Gas Inc is a regulated natural gas utility company. It is involved in the distribution and sale of natural gas to residential, commercial, industrial, and transportation consumers through its network of pipelines and service lines. Almost all of the company's revenue is derived from natural gas sales in the states of Oklahoma, Kansas, and Texas. It operates in one reportable business segment: regulated public utilities that deliver natural gas to residential, commercial, and transportation customers.
iRhythm Holdings Inc formerly, iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.